CASADEI GARDINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.307
EU - Europa 2.899
AS - Asia 1.459
SA - Sud America 31
AF - Africa 14
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.724
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.278
GB - Regno Unito 1.471
SG - Singapore 475
SE - Svezia 414
IT - Italia 337
CN - Cina 300
DE - Germania 243
HK - Hong Kong 169
TR - Turchia 160
VN - Vietnam 156
BG - Bulgaria 103
FR - Francia 80
FI - Finlandia 79
ID - Indonesia 75
IN - India 38
IE - Irlanda 34
BE - Belgio 25
BR - Brasile 19
CA - Canada 18
JP - Giappone 18
TH - Thailandia 17
RU - Federazione Russa 16
NL - Olanda 15
RO - Romania 13
EG - Egitto 11
AT - Austria 9
AU - Australia 9
BZ - Belize 9
UA - Ucraina 9
CH - Svizzera 8
IR - Iran 8
KR - Corea 8
NO - Norvegia 8
MY - Malesia 7
PK - Pakistan 7
LT - Lituania 6
ES - Italia 5
TW - Taiwan 5
CL - Cile 4
IQ - Iraq 4
LU - Lussemburgo 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
CZ - Repubblica Ceca 3
SA - Arabia Saudita 3
GR - Grecia 2
LK - Sri Lanka 2
LV - Lettonia 2
MT - Malta 2
NZ - Nuova Zelanda 2
PE - Perù 2
PL - Polonia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
EC - Ecuador 1
HU - Ungheria 1
KH - Cambogia 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MX - Messico 1
PA - Panama 1
PS - Palestinian Territory 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
VE - Venezuela 1
Totale 15.724
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Southend 1.304
Ashburn 1.007
Santa Clara 971
Woodbridge 907
Seattle 871
Houston 776
Cambridge 732
Chandler 692
Wilmington 674
Singapore 405
Dearborn 324
Nyköping 307
Ann Arbor 300
Hong Kong 166
San Diego 158
Izmir 156
Dong Ket 155
Princeton 103
Sofia 103
Eugene 93
Phoenix 80
Helsinki 79
Jakarta 74
Beijing 72
London 72
New York 71
Modena 63
Bremen 47
Dublin 33
Redwood City 28
Shanghai 27
Milan 24
Boardman 23
Brussels 20
Norwalk 20
San Mateo 18
Bologna 17
Chicago 16
Kunming 16
Hefei 14
Munich 14
Tokyo 13
Dallas 12
Paris 12
San Jose 12
Falls Church 11
Nanjing 11
Zhengzhou 11
Guangzhou 10
Hounslow 10
Kilburn 10
Ottawa 10
Amsterdam 9
Belize City 9
Grafing 9
Jacksonville 9
Monmouth Junction 9
Mumbai 9
Chiswick 8
Hanover 8
Rome 8
Saint Louis 8
Bari 7
Jinan 7
Catania 6
Edinburgh 6
Atlanta 5
Frankfurt am Main 5
Fremont 5
Islington 5
Nanchang 5
Vienna 5
Ardabil 4
Augusta 4
Forlì 4
Geneve 4
Genoa 4
Melbourne 4
Monsampolo Del Tronto 4
Prescot 4
Saint-Fons 4
San Francisco 4
Taipei 4
Toronto 4
Turin 4
Al Qahirah al Jadidah 3
Baranzate 3
Buscoldo 3
Chennai 3
Clearwater 3
Columbus 3
Florence 3
Forlimpopoli 3
Gunzenhausen 3
Hangzhou 3
Los Angeles 3
Massa Lombarda 3
Mountain View 3
Oslo 3
Totale 13.602
Salva come PNG Salva come JPEG
Nome #
Chemotherapy and palliative care near end-of life: Examining the appropriateness at a cancer institute for colorectal cancer patients 532
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 446
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 234
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 229
Immunotherapy for colorectal cancer: where are we heading? 228
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 223
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 206
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 203
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 195
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 190
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 189
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 185
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 184
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 183
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 181
Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results 179
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 178
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 178
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 177
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 177
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial 176
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 176
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 175
Sarcopenia in gastric cancer: when the loss costs too much 175
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 174
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 173
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 172
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 172
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 171
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 171
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 169
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 168
The Italian Rare Pancreatic Exocrine Cancer Initiative 167
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 167
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 164
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 163
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials 162
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 162
Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy 162
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 162
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 161
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 161
Metabolic disorders across hepatocellular carcinoma in Italy 160
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 160
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 160
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 159
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 159
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 158
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 156
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial 156
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 155
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 154
Improved stool DNA integrity method for early colorectal cancer diagnosis 153
Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes 152
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 152
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 152
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 152
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib 152
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 151
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial 151
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 150
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 150
Immunotherapeutic approaches for hepatocellular carcinoma 149
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 148
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 145
Treatment of squamous cell carcinoma of the anal canal (SCCA): A new era? 145
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 143
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer 143
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 142
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 142
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 142
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 141
Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study 140
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 136
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 134
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence 134
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 132
Clustered protocadherins methylation alterations in cancer 131
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 131
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial 130
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab 130
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 127
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 127
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 123
Increase of reports of suspected adverse drug reactions in oncology 121
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 120
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 119
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 113
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 110
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 108
Hemangioblastoma of the gastrointestinal tract: A first case 103
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 99
BRAF-mutated colorectal cancer: Clinical and molecular insights 82
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 82
Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis 80
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 78
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 74
Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma 73
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 70
Early detection of cardiotoxicity in chemotherapy-treated patients from real-time 3D echocardiography 60
Totale 15.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.943
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.943
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.908 0 0 0 0 0 691 752 568 375 226 204 92
2020/20214.028 412 122 203 504 389 415 177 384 274 396 383 369
2021/20222.268 318 153 159 113 68 185 81 122 224 259 376 210
2022/20232.022 227 196 130 174 279 237 65 215 288 21 94 96
2023/2024900 41 77 50 120 141 32 68 126 22 25 29 169
2024/20251.536 133 39 33 256 957 118 0 0 0 0 0 0
Totale 16.044